Nabriva Therapeutics plc - NBRV STOCK NEWS

Nabriva Therapeutics has announced that its extraordinary general meeting of shareholders (EGM), originally scheduled for December 22, 2021, will be adjourned and reconvened on January 14, 2022. This decision allows the company to solicit additional proxies necessary for the approval of its proposal outlined in a November 22, 2021 proxy statement. Shareholders can vote through various methods including online, by phone, mail, or in person. The record date remains November 19, 2021.

Nabriva Therapeutics (NASDAQ: NBRV) recently announced that CEO Ted Schroeder will present a company overview at the H.C. Wainwright BioConnect Virtual Conference, starting January 10, 2022, at 7:00 AM ET. The presentation will be available on-demand and can be accessed via the Investors section of the Nabriva website. Management will also host investor meetings from January 10-13, 2022. The company specializes in developing innovative anti-infective agents, including XENLETA® and CONTEPO™, aimed at treating serious infections.

Nabriva Therapeutics (NASDAQ: NBRV) announced that its partner, Sumitomo Pharmaceuticals (Suzhou), received acceptance for their new drug application (NDA) to market lefamulin in China for treating community-acquired pneumonia (CAP). This NDA was accepted by the Chinese Center for Drug Evaluation on November 23, 2021. Lefamulin is anticipated to be the first-in-class treatment for CAP patients in China. This marks the sixth global filing for lefamulin, with four previous approvals and two applications under review.

Nabriva Therapeutics (NASDAQ: NBRV) announced that its oral formulation of XENLETA (lefamulin) is now available in a 10-count pack in the U.S., enhancing retail access. XENLETA is the first pleuromutilin antibiotic for treating community-acquired bacterial pneumonia (CABP) with a unique mechanism that minimizes resistance. This new package allows pharmacies to better meet patient needs. Ted Schroeder, CEO, emphasized the benefits for pharmacies and patients. XENLETA has shown efficacy similar to moxifloxacin in clinical trials involving 1,289 patients.

Nabriva Therapeutics plc (NASDAQ: NBRV) reported Q3 2021 revenues of $8.9 million, an 8% increase from Q2 2021, driven by a 14% growth in SIVEXTRO net sales and prescriptions. The company extended its cash runway through Q2 2022, with cash and equivalents of $52.0 million as of September 30, 2021. Net loss improved to $10.7 million from $13.0 million a year earlier. The firm launched an in-house promotion for XENLETA and partnered with Vizient Health to increase access in hospitals. Notable regulatory updates include the approval of XENLETA in Taiwan.

Nabriva Therapeutics (NASDAQ: NBRV) announced that CEO Ted Schroeder will present a company overview at the Jefferies London Healthcare Conference. The presentation will be available on-demand from November 18 at 8:00 AM GMT until November 19 at 5:00 PM GMT. Investors can access the presentation via the Company's website. Nabriva specializes in developing anti-infective agents, including XENLETA® for treating community-acquired bacterial pneumonia and CONTEPO™ for complicated urinary tract infections. The company has also partnered with Merck to market SIVEXTRO® in the U.S.

Nabriva Therapeutics (NASDAQ: NBRV) announced the granting of a non-statutory stock option for 100,000 ordinary shares to new Chief Medical Officer Christine Guico-Pabia. The option, effective October 29, 2021, has an exercise price of $1.15 per share, matching Nabriva's closing stock price on that date. It vests over four years and was granted under Nasdaq's inducement grant exception as part of her employment compensation.

Nabriva specializes in developing anti-infective agents, including XENLETA and CONTEPO.

Nabriva Therapeutics (NASDAQ: NBRV) will announce its third quarter financial results on November 9, 2021, after U.S. market close. The company specializes in innovative anti-infective agents for serious infections, especially XENLETA® for community-acquired bacterial pneumonia and CONTEPO™ for complicated urinary tract infections. Following the earnings release, management will host a conference call at 4:30 p.m. ET to discuss the results and company highlights. Investors can participate via dial-in or listen to a live webcast on Nabriva's website.

Nabriva Therapeutics (NASDAQ: NBRV) announced it will present data at CHEST 2021, the annual meeting of the American College of CHEST Physicians, occurring virtually from October 17-20, 2021. Dr. Thomas M. File will discuss the efficacy and safety of Lefamulin in treating community-acquired bacterial pneumonia during his session on October 17, 2021, at 11:45 AM ET. Lefamulin is a first-in-class antibiotic approved for this indication, and Nabriva is also developing CONTEPO for complicated urinary tract infections and marketing SIVEXTRO through an agreement with Merck.